Monitor the May 15 call for extended follow-up data from the Phase 3 prostate cancer trial; positive efficacy or safety signals could drive significant upside for CADL. The stock may trade on anticipation ahead of the AUA presentation.
Price Chart
Executive Summary
Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data from the Phase 3 trial of CAN-2409 in prostate cancer, following an oral plenary presentation at AUA 2026. The call features key opinion leaders, but no new data or regulatory decision is disclosed in this press release, making it a routine event update.
Key Facts
- Conference call scheduled for May 15, 2026, at 1:00 PM ET to discuss Phase 3 extended follow-up data for CAN-2409 in intermediate- to high-risk localized prostate cancer.
- Data will be presented as an oral plenary at the AUA 2026 Annual Meeting.
- Call will feature insights from leading prostate cancer specialists including Drs. Shore, Tward, and George.
- CAN-2409 has FDA Fast Track and Regenerative Medicine Advanced Therapy Designations for prostate cancer.
- No new clinical data, regulatory updates, or financial figures are provided in this press release.
Financial Impact
No financial impact disclosed; event is a data presentation update.
Risk Factors
- Extended follow-up data may not show statistically significant improvement over placebo.
- Regulatory path for CAN-2409 remains uncertain pending full data readout.
- Clinical-stage biotech carries high risk of trial failure or delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286676 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 27d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 $8.16 | ▼ −18.97% | ▼ −20.75% | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers